Biologics

(SLA-037) Can observational studies replace experimental transition (or switching) studies for evaluating the interchangeability of biological drug reference and biosimilars? Methodological challenges and considerations

(SLA-034) Cardiovascular Disease Risk Among Patients Using Tumor Necrosis Factor-Alpha Inhibitors and Milk Consumption: A Population-Based Study

(SLA-039) Effect of Achieving Pain Relief between Baricitinib and Tofacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study using the TriNetX Global Collaborative Networks.

(SLA-033) Integration of Two Large Databases for an Observational Cohort Study of Exposure to Galcanezumab during Pregnancy among Women with Migraine

(A-034) Long-Term Safety of Fingolimod in Multiple Sclerosis: A Scoping Review of Randomized Controlled Trial and Real-World Studies

(SLA-035) Research and Development Costs for Biologic Products Developed by U.S. Biotechnology Startups, 2017-2023

(SLA-038) Single and multiple switches, swap and retransitioning among 28,073 biological drug users with inflammatory bowel disease: results from Italian VALORE distributed database network

(A-033) Utilization of erenumab and other prophylactic migraine treatments: a regulator-mandated population-based cohort study in four Nordic countries (EUPAS36014)